Hancock Whitney’s Charles River Laboratories CRL Stock Holding History

Hancock Whitney’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,615	Closed	-$396K	–	563
2017 Q4	$396K	Sell	3,615 -200	-5%	-$21.8K	0.02%	466
2017 Q3	$412K	Sell	3,815 -1,811	-32%	-$186K	0.02%	446
2017 Q2	$569K	Sell	5,626 -1,135	-17%	-$104K	0.02%	406
2017 Q1	$608K	Sell	6,761 -26,275	-80%	-$2.23M	0.03%	417
2016 Q4	$2.52M	Buy	33,036 +1,195	+4%	+$90.8K	0.09%	243
2016 Q3	$2.65M	Buy	+31,841	New	+$2.67M	0.11%	240
2015 Q3	–	Sell	-12,620	Closed	-$1M	–	531
2015 Q2	$1M	Hold	12,620	–	–	0.04%	280
2015 Q1	$1M	Buy	12,620 +2,020	+19%	+$149K	0.04%	280
2014 Q4	$675K	Hold	10,600	–	–	0.03%	339
2014 Q3	$633K	Buy	10,600 +1,100	+12%	+$62.9K	0.02%	330
2014 Q2	$508K	Hold	9,500	–	–	0.02%	381
2014 Q1	$573K	Hold	9,500	–	–	0.02%	340
2013 Q4	$504K	Hold	9,500	–	–	0.02%	354
2013 Q3	$439K	Buy	+9,500	New	+$436K	0.02%	388

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hancock Whitney's CRL Position: Q1 2018 in Review

Hancock Whitney sold out of Charles River Laboratories (CRL) in Q1 2018, closing a stake of 3,615 shares — an estimated $396K sold.

Hancock Whitney first reported a position in CRL in Q3 2013 and held it in 14 quarters. The position peaked at $2.65M in Q3 2016. 333 funds tracked by Wall St. Rank hold CRL as of Q1 2018.

Hancock Whitney reported no remaining Charles River Laboratories position as of Q1 2018 after selling out during the quarter.
Hancock Whitney sold 3,615 Charles River Laboratories shares in Q1 2018, an estimated $396K.
Hancock Whitney first reported a position in Charles River Laboratories in Q3 2013 and held it in 14 quarters.
Hancock Whitney's Charles River Laboratories position peaked at $2.65M in Q3 2016.
333 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2018.

Based on Hancock Whitney's 13F filing for Q1 2018, filed 15 May 2018.